Skip to main content

Table 3 Outcomes of the subgroup analysis

From: Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis

  No. of studies Heterogeneity test Effect size
I2 (%) PH WMD/RR (95% CI) P
Platelet reactivity (PRU)
 Type of studies
  RCT 5 86 < 0.001 −29.93 (−70.21, 10.36) 0.15
  Cohort 2 87 0.005 −37.55 (−65.66, −9.44) 0.009
 Testing time
   < 24 h after the loading dose 3 87 0.005 −22.48 (−105.72, 60.76) 0.60
  5–30 days after initiation of treatment 4 76 0.006 −36.72 (−57.04, −16.40) < 0.001
 Special Population
  STEMI 3 67 0.05 −5.77 (−34.85, −23.31) 0.70
  Diabetic patients 1 − 10.90 (−43.61, 21.81) 0.514
Platelet reactivity (PRI)
 Type of studies
  RCT 5 88 < 0.001 −10.51 (− 16.17, −4.85) < 0.001
  Cohort 2 0 0.319 −5.36 (−9.97, −0.76) 0.023
 Testing time
   < 24 h after the loading dose 3 89 < 0.001 −10.30 (−19.70, −0.90) 0.032
  5–30 days after initiation of treatment 4 81 < 0.001 −8.91 (−15.03, −2.79) 0.004
 Special Population
  STEMI 2 0 0.650 −3.69 (−7.63, 0.26) 0.067
  Diabetic patients 1 −10.40 (−17.96, −2.84) 0.007
HTPR rates (PRU) a
 Type of studies
  RCT 1 5.00 (0.25, 99.51) 0.29
  Cohort 1 0.03 (0.00, 0.52) 0.016
 Testing time
  5–30 days after initiation of treatment 2 84 0.01 0.39 (0.001, 62.72) 0.71
HTPR rates (PRI)
 Type of studies
  RCT 5 20 0.290 0.30 (0.12, 0.75) 0.010
 Testing time
   < 24 h after the loading dose 2 0 0.440 0.31 (0.10, 0.98) 0.047
  5–30 days after initiation of treatment 3 69 0.073 0.24 (0.03, 2.08) 0.197
 Special Population
  STEMI 1 0.11 (0.01, 2.00) 0.137
  Diabetic patients 1 0.38 (0.11, 1.33) 0.129
LTPR rates (PRI)
 Type of studies
  RCT 4 82 0.0008 1.63 (0.95, 2.80) 0.073
  Cohort 2 85 0.009 1.31 (0.98, 1.76) 0.066
 Testing time
   < 24 h after the loading dose 2 0 0.898 1.09 (0.86, 1.39) 0.462
  5–30 days after initiation of treatment 4 89 < 0.001 1.69 (1.12, 2.56) 0.012
 Special Population
  STEMI 2 0 0.634 1.15 (1.01, 1.30) 0.029
  Diabetic patients 1 1.11 (0.79, 1.56) 0.545
  1. a three studies don’t involved in the results of STEMI or Diabetic patients